# Does Iowa Medicaid Cover Wegovy? One Form, Three Routes, No Weight Loss By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-11-06 Canonical page: https://glpwatchdog.org/research/iowa-medicaid-glp1-coverage > Iowa's rule shuts out weight-loss drugs, but its October 2026 drug list prefers both Wegovy and Zepbound for other uses. Form 470-0058 covers heart disease on a broad list, MASH and sleep apnea. Criteria, the diabetes route, filing and appeal windows. ## Key points - State rule bars payment for weight-loss drugs, and the drug list repeats that weight loss is not covered for Wegovy or Zepbound. - Both drugs are preferred, and form 470-0058 handles heart disease, MASH and sleep apnea requests together. - The heart route counts heart failure, atrial fibrillation and past blood clots as established disease, from age 18 with a BMI of 27. - Zepbound needs a BMI of 30 and an AHI of 15 on a sleep study up to three years old, with no CPAP step. - Iowa lists a 90-day window to appeal a Medicaid decision. From December 1, 2026, Optum Rx reviews pharmacy prior authorizations for managed care members too. No. Iowa Medicaid will not pay for Wegovy to treat weight alone: its drug list marks Wegovy and Zepbound “weight loss indication not covered,” and state rule bars payment for weight-loss drugs.[1][4] As of November 2026, both are preferred drugs that a prior authorization can approve for three other uses: Wegovy to lower heart risk in adults with cardiovascular disease, Wegovy for the liver disease MASH, and Zepbound for moderate to severe sleep apnea.[3] > **About this article.** This page reads Iowa Medicaid’s drug list and its prior authorization criteria, both effective October 1, 2026, form 470-0058 as revised in October 2026, and the state’s October 16, 2026 notice moving pharmacy prior authorizations to Optum Rx, as they stood on November 6, 2026. Iowa revises these documents several times a year. To see how other states handle the same drugs, use the [state Medicaid GLP-1 checker](https://glpwatchdog.org/tools/state-medicaid-glp1-checker). ## Does Iowa Medicaid cover Wegovy for weight loss? No. Iowa’s administrative code lists drugs used for weight loss, weight gain or anorexia among the drugs it will not pay for.[4] The prior authorization criteria repeat it for the diabetes drugs (requests for weight loss “will be denied”) and for Wegovy and Zepbound, where the form says payment for weight loss as an excluded use will be refused.[2][3] Under federal law, states may make that choice.[9] Our explainer on [how Medicaid handles Ozempic and Wegovy](https://glpwatchdog.org/research/does-medicaid-cover-ozempic-and-wegovy) covers the federal background. Your managed care plan does not change the rule. Iowa Total Care, one of the state’s plans, says it follows the state drug list to decide which drugs are covered and which need prior authorization.[5] That job is moving to the state. Starting December 1, 2026, Iowa Medicaid will run the pharmacy benefit for managed care members itself, and Optum Rx, its pharmacy vendor, will review all outpatient pharmacy prior authorizations.[15] Plans accept pharmacy requests until 4:00 p.m. Central on November 30, 2026, and Optum Rx will honor an active plan approval for as long as it lasts.[15] ## What does Iowa Medicaid cover instead? *Iowa Medicaid GLP-1 rules from the drug list and criteria effective October 1, 2026* | Use | Drug | List status | Main requirements | | --- | --- | --- | --- | | Weight loss | Wegovy, Zepbound, all GLP-1s | Excluded | No route | | Type 2 diabetes | Mounjaro, Ozempic, Trulicity, Victoza, Rybelsus, exenatide | Preferred, PA required | A current A1C; no DPP-4 drug at the same time | | Heart-risk reduction | Wegovy (injection or tablet) | Preferred, PA required | Age 18+; established heart or vascular disease; BMI of at least 27 in the past 6 months; standard heart care reviewed | | Moderate to severe sleep apnea | Zepbound | Preferred, PA required | Adult; BMI 30 or more; 15 or more apnea events an hour on a sleep study done in the past 3 years | | MASH with F2 to F3 fibrosis | Wegovy injection | Preferred, PA required | FibroScan 8 to 15 kPa, MRE 3.1 to 4.4 kPa or biopsy; no heavy drinking in the past year | The diabetes route is lighter than in many states. A preferred GLP-1 for type 2 diabetes needs a current A1C result, with no stated metformin trial, and Mounjaro is preferred alongside Ozempic.[1][2] A non-preferred diabetes drug, such as generic liraglutide, requires failed trials of at least three preferred drugs from three classes.[2] ## Will Iowa Medicaid cover Wegovy for heart disease? Yes, and Iowa reads “established cardiovascular disease” broadly. The form accepts coronary artery disease, including angina or a past heart attack; stroke or a transient ischemic attack; peripheral artery disease; heart failure; atrial fibrillation and other rhythm problems; valve disease; congenital heart disease; cardiomyopathy; aortic aneurysm or dissection; and a past deep vein clot or pulmonary embolism.[3] The adult must have a BMI of at least 27 measured within six months, and the prescriber confirms that standard heart care has been reviewed.[3] That is wider than the trial behind the label. SELECT enrolled people 45 and older with a past heart attack, stroke or symptomatic artery disease, a BMI from 27 up, and no diabetes.[12] The label itself says only “established” heart disease with obesity or overweight, and Iowa’s form follows the label, setting the minimum age at 18 rather than 45.[3][10] The form also asks nothing about diabetes, so a person with type 2 diabetes and heart disease is not shut out of this route by its text.[3] For a person with diabetes, the diabetes route is usually simpler anyway. The tablet form of Wegovy can be requested on the same form, and both versions must reach a set maintenance dose: 1.7 or 2.4 mg a week for the injection, 25 mg a day for the tablet, with up to eight weeks at each step on the way.[3] ## Does Iowa Medicaid cover Zepbound for sleep apnea? Yes. Zepbound is preferred for moderate to severe obstructive sleep apnea when the baseline BMI is at least 30 and a lab or home sleep study from the past three years shows an apnea-hypopnea index (AHI) of 15 or above.[3] The patient must meet the FDA’s age for this use, which the label limits to adults with obesity.[3][11] The form has no CPAP step and does not require a sleep specialist.[3] The three-year window for the sleep study is generous, since several states want a test from the past year. Zepbound must reach a maintenance dose of 10 to 15 mg within 20 weeks, and renewals ask for documentation that the treatment is working.[3] Our guide to [Zepbound for sleep apnea](https://glpwatchdog.org/research/zepbound-for-sleep-apnea) covers the trials behind the indication. ## What does Iowa require for Wegovy and MASH? Proof of the fibrosis stage. The adult must have noncirrhotic MASH with F2 to F3 fibrosis, confirmed by a FibroScan reading of 8 to 15 kPa, a magnetic resonance elastography reading of 3.1 to 4.4 kPa, or a liver biopsy with an activity score of 4 or more.[3] The patient cannot have had heavy alcohol use in the past year, defined as more than 20 grams a day for women or 30 grams for men.[3] Iowa considers Wegovy together with Rezdiffra, the other MASH drug, only after each has been tried alone at a full dose without enough response.[3] Renewals need evidence of benefit, such as stable or better fibrosis or lower liver enzymes, and no progression to cirrhosis.[3] The label notes that this use rests on accelerated approval.[10] Our review of [GLP-1s for MASH](https://glpwatchdog.org/research/glp1-and-fatty-liver-mash) covers the trial, and our comparison of Rezdiffra and semaglutide explains the choice between them. ## How do you file and renew an Iowa request? The prescriber faxes form 470-0058 to 1-800-574-2515; the provider help desk is 1-877-776-1567.[3] From December 1, 2026, Optum Rx reviews these requests for managed care members as well, and that help desk number is the one Iowa lists for its pharmacy prior authorization line.[15] All three uses also require that the patient pair the drug with diet and activity changes and not take a second GLP-1.[3] Once the patient reaches a maintenance dose, continuation requests are reviewed at 12-month intervals.[2] ## How do you appeal an Iowa Medicaid denial? Check the reason first. A missing BMI date, sleep study or fibrosis result can often be fixed by sending the record again, but a request for weight loss alone has no route to win.[2] Iowa’s Department of Health and Human Services lists a 90-day window to appeal a Medicaid decision, and its appeals line is 1-888-723-9637.[6] If a managed care plan denied the request, which applies to requests the plans decide through November 30, 2026, federal rules apply first. A plan member has 60 days from the plan’s denial notice to file an appeal with the plan, then 90 days or more after the plan decides to ask the state for a fair hearing.[7][8] Iowa’s notice on the December 1 change does not say how appeals of Optum Rx decisions will work, so follow the route and deadline printed on your denial notice.[15] Our walkthrough of [prior authorization and appeals](https://glpwatchdog.org/research/glp1-prior-authorization-and-appeals) covers what to include, and the [Iowa state page](https://glpwatchdog.org/states/iowa) summarizes the Medicaid facts. ## What if Iowa Medicaid will not pay? Paying cash is the usual fallback, and Lilly’s savings card terms exclude anyone in Medicaid.[13] In the prices we track, Novo Nordisk charges $349 a month for most Wegovy pen doses, while Lilly charges $299 for the 2.5 mg starting dose, $399 at 5 mg and $449 at 7.5 mg and up when each refill comes within 45 days.[13][14] Read each program’s rules on government coverage before you sign up. We compare these offers in our roundup of [ways to pay less for a GLP-1 without coverage](https://glpwatchdog.org/research/cheapest-glp1-without-insurance). ## Frequently asked questions ### Does Iowa Medicaid cover Wegovy? Not for weight loss. As of November 2026, Wegovy is a preferred drug that can be approved with prior authorization for an adult with established heart or vascular disease and a BMI of at least 27, or for MASH liver disease with F2 to F3 fibrosis. ### Does Iowa Medicaid cover Zepbound? Only for sleep apnea. Zepbound is preferred for adults with moderate to severe obstructive sleep apnea, a BMI of 30 or more, and a sleep study from the past three years showing 15 or more apnea events an hour. Iowa does not require a CPAP trial first. ### Does Iowa Medicaid cover Ozempic or Mounjaro for diabetes? Yes. Both are preferred drugs for type 2 diabetes that need prior authorization, and the criteria ask for a current A1C result. Requests to use either drug for weight loss are denied. ### Can someone with diabetes get Wegovy for heart disease in Iowa? The October 2026 form for heart-risk requests does not ask about diabetes or exclude it. In practice, a person with type 2 diabetes and heart disease can also use the diabetes route, where Ozempic and Mounjaro are preferred. ### How long do I have to appeal an Iowa Medicaid denial? Iowa's health department lists 90 days to appeal a Medicaid decision. If a managed care plan denied the request, you first appeal to the plan within 60 days of its denial notice, then can ask for a state fair hearing after the plan decides. From December 1, 2026, Optum Rx decides pharmacy prior authorizations for all Iowa Medicaid members, so check the route and dates printed on your notice. ## References 1. Iowa Department of Health and Human Services, Iowa Medicaid Preferred Drug List, effective October 1, 2026. iowamedicaidpdl.com. 2026. https://www.iowamedicaidpdl.com/content/dam/ffs-medicaid/ia/iowa-pdl-01-2026.pdf 2. Iowa Department of Health and Human Services, Iowa Medicaid Iowa Medicaid Drug Prior Authorization Criteria, updated October 1, 2026. iowamedicaidpdl.com. 2026. https://www.iowamedicaidpdl.com/content/dam/ffs-medicaid/ia/pa-criteria-chart-effective-oct-2026.pdf 3. Iowa Department of Health and Human Services, Iowa Medicaid Form 470-0058 (10/26): Request for Prior Authorization, Incretin Mimetics for Non-Diabetes Indications. iowamedicaidpdl.com. 2026. https://www.iowamedicaidpdl.com/content/dam/ffs-medicare/ia/pa-forms/incretin-mimetics-non-diabetes-pa-form-npi-oct-26.pdf 4. State of Iowa Iowa Administrative Code 441-78.2: Prescribed outpatient drugs. Iowa Legislature. 2026. https://www.legis.iowa.gov/docs/iac/rule/441.78.2.pdf 5. Iowa Total Care Pharmacy information for providers. iowatotalcare.com. 2026. https://www.iowatotalcare.com/providers/pharmacy.html 6. Iowa Department of Health and Human Services Appeal an HHS Decision. hhs.iowa.gov. 2026. https://hhs.iowa.gov/programs/appeals/how-appeal 7. Code of Federal Regulations 42 CFR §438.402: Grievance and appeal systems, general requirements. Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/cfr/text/42/438.402 8. Code of Federal Regulations 42 CFR §438.408: Resolution and notification of grievances and appeals. Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/cfr/text/42/438.408 9. United States Code 42 U.S.C. §1396r-8: Payment for covered outpatient drugs (Social Security Act §1927). Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/uscode/text/42/1396r-8 10. Novo Nordisk WEGOVY (semaglutide) injection and tablets: prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b 11. Eli Lilly and Company ZEPBOUND (tirzepatide) injection: prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b 12. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023. PMID: 37952131. DOI: 10.1056/NEJMoa2307563. https://pubmed.ncbi.nlm.nih.gov/37952131/ 13. Eli Lilly and Company Zepbound savings and self-pay options, with card terms. zepbound.lilly.com. 2026. https://zepbound.lilly.com/savings 14. Novo Nordisk Wegovy savings offer. novocare.com. 2026. https://www.novocare.com/obesity/products/wegovy/savings-offer.html 15. Iowa Department of Health and Human Services, Iowa Medicaid Informational Letter No. 2742-MC-FFS: Pharmacy Benefit Carve-Out (October 16, 2026; effective December 1, 2026). iowamedicaidpdl.com. 2026. https://www.iowamedicaidpdl.com/content/dam/ffs-medicaid/ia/ia-2742-pharmacy-benefit-carve-out.pdf --- Cite as: GLP Watchdog, Nora Bissett, "Does Iowa Medicaid Cover Wegovy? One Form, Three Routes, No Weight Loss", published 2026-11-06. https://glpwatchdog.org/research/iowa-medicaid-glp1-coverage Canonical HTML page: https://glpwatchdog.org/research/iowa-medicaid-glp1-coverage Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.